P3 Health Partners forecasts $80M-$110M in 2026 adjusted EBITDA following Q2 settlements (NASDAQ:PIII)
P3 Health Partners (PIII) Q2 2026 earnings call recap: EBITDA beat, raised 2026 outlook, settlement impacts, seasonality risks & strategy.
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
P3 Health Partners (PIII) Q2 2026 earnings call recap: EBITDA beat, raised 2026 outlook, settlement impacts, seasonality risks & strategy.
P3 Health Partners forecasts $80M-$110M in 2026 adjusted EBITDA following Q2 settlements (NASDAQ:PIII) | Seeking Alpha
Earnings Call Insights: P3 Health Partners (PIII) Q2 2026
Management View
âWe delivered $54 million of adjusted EBITDA in the second quarter⦠Given this strong performance and our confidence in the underlying business, we are raising our full year 2026 outlook,â said CEO Aric
Seeking Alpha's Disclaimer:
This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Quick Insights
How much of P3 Health's Q2 2026 earnings were driven by nonrecurring settlements?
A significant portion of Q2 earnings came from one-time nonrecurring items; about $45 million of the Q2 results included favorable payer settlements and prior year developments.
How durable and predictable is P3 Health's underlying profitability, excluding settlements?
Underlying Q2 adjusted EBITDA (excluding one-time settlements) was about $9 million, and management emphasized separating recurring core performance from settlement-driven volatility; confidence is rising in earnings durability, but some risk remains.
What are the key risks to P3 Health's raised adjusted EBITDA outlook for 2026?
Key risks include typical seasonal increases in medical costs in the second half, volatile settlement contributions, and limited current visibility into 2027 plan changes or market exits.
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
Rapid7's 2026 Exit Signal: Deep Dive into 20% Margin Target and 12% Workforce Restructuring
Rapid7 announces 2026 exit plan with ~20% non-GAAP operating margin target and 12% workforce restructuring. This analysis explores strategic intent, financial feasibility, and industry context for investors.
Anaergia reports Q2 results (TSX:ANRG:CA)
Anaergia press release (ANRG:CA): Q2 Revenue of C$63.9M (+97.8% Y/Y). Adjusted EBITDA improved to positive C$1.9 million, compared with an Adjusted EBITDA loss
QuidelOrtho partially recovers from earnings slide, rising 12% (QDEL:NASDAQ)
QuidelOrtho (QDEL) stock rebounds 12% after Q2 earnings beat but sharp 2026 guidance cut.
Bowman Consulting Non-GAAP EPS of $0.62 beats by $0.16, revenue of $146.12M beats by $0.32M (NASDAQ:BWMN)
Bowman Consulting press release (BWMN): Q2 Non-GAAP EPS of $0.62 beats by $0.16. Revenue of $146.12M (+19.7% Y/Y) beats by $0.32M. Full Year 2026 Guidance Bowma